نتایج جستجو برای: anthracyclines

تعداد نتایج: 3200  

Journal: :Molecular pharmacology 2002
Juliana C Kwok Des R Richardson

Anthracyclines are effective antineoplastic agents. However, the interaction of these drugs with iron (Fe) is an important cause of myocardial toxicity, limiting their therapeutic use (J Lab Clin Med 122:245-251, 1993). To overcome this limitation, it is crucial to understand how anthracyclines interact with the Fe metabolism of myocardial and neoplastic cells. Iron-regulatory proteins (IRPs) p...

Journal: :Journal of the National Cancer Institute 2008
Alessandra Gennari Maria Pia Sormani Paolo Pronzato Matteo Puntoni Mariantonietta Colozza Ulrich Pfeffer Paolo Bruzzi

BACKGROUND Adjuvant chemotherapy with anthracyclines improves disease-free and overall survival compared with non-anthracycline-based adjuvant chemotherapy regimens in the treatment of early breast cancer. The role of HER2 status as a marker of anthracycline responsiveness has been explored by subset analyses within randomized clinical trials, with inconsistent results. We performed a pooled an...

Journal: :Cancer research 2003
Luther Swift Jane McHowat Narine Sarvazyan

Administration of anthracyclines, a family of highly effective anticancer drugs, is associated with a cumulative dose-related cardiomyopathy, the etiology of which remains poorly understood. We have discovered that administration of the anthracyclines leads to a marked inhibition of membrane-associated calcium-independent phospholipase A(2) (iPLA(2)) both in vitro and in vivo. To elucidate the ...

Journal: :Chemotherapy 2017
Pierantonio Menna Emanuela Salvatorelli

The clinical use of doxorubicin and other antitumor anthracyclines is limited by a dose-related risk of cardiomyopathy and heart failure which may occur "on treatment" or any time, from months to years, after completing chemotherapy. Dose reductions diminish the incidence of cardiac events attributable to anthracyclines, but heart failure still occurs in some patients exposed to low or moderate...

Journal: :Mutation research 2015
Fan Yang Christopher J Kemp Steven Henikoff

Doxorubicin is a widely used chemotherapeutic drug that intercalates between DNA base-pairs and poisons Topoisomerase II, although the mechanistic basis for cell killing remains speculative. Doxorubicin and related anthracycline compounds have been shown to increase nucleosome turnover and/or eviction around promoters, which suggests that the resulting enhanced exposure of DNA might underlie ce...

Journal: :Molecular pharmacology 2003
J C Kwok D R Richardson

Anthracyclines are potent antitumor agents that cause cardiotoxicity at high cumulative doses. Because anthracycline cardiotoxicity is attributed to their ability to avidly bind iron (Fe), we examined the effect of anthracyclines on intracellular Fe trafficking in neoplastic cells and differentiated cardiomyocytes. In both cell types, incubation with doxorubicin (DOX) resulted in a significant ...

2010
Filippo Montemurro Valentina Rossi Franco Nolè Stefania Redana Michela Donadio Rossella Martinello Elena Verri Giorgio Valabrega Maria Cossu Rocca Maria Elena Jacomuzzi Giuseppe Viale Anna Sapino Massimo Aglietta

Anthracyclines are among the most active drugs in breast cancer. Because of excessive cardiotoxicity, their use in combination with trastuzumab has been discouraged in patients with human epidermal growth factor receptor (HER)-2(+) metastatic breast cancer. We sought to describe how this treatment paradigm influenced the use of anthracyclines in this patient setting. We analyzed a multi-institu...

Journal: :Circulation. Cardiovascular imaging 2012
Heloisa Sawaya Igal A Sebag Juan Carlos Plana James L Januzzi Bonnie Ky Timothy C Tan Victor Cohen Jose Banchs Joseph R Carver Susan E Wiegers Randolph P Martin Michael H Picard Robert E Gerszten Elkan F Halpern Jonathan Passeri Irene Kuter Marielle Scherrer-Crosbie

BACKGROUND Because cancer patients survive longer, the impact of cardiotoxicity associated with the use of cancer treatments escalates. The present study investigates whether early alterations of myocardial strain and blood biomarkers predict incident cardiotoxicity in patients with breast cancer during treatment with anthracyclines, taxanes, and trastuzumab. METHODS AND RESULTS Eighty-one wo...

Journal: :Acta biochimica Polonica 2009
Krzysztof Kik Kazimierz Studzian Małgorzata Wasowska-Łukawska Irena Oszczapowicz Leszek Szmigiero

UNLABELLED This work was undertaken to compare cytotoxicity, DNA damaging properties and effect on DNA cleavage by topoisomerase II of the anthracycline drug doxorubicin (DOX) and its two derivatives with a formamidino group containing a cyclic amine moiety such as morpholine (DOXM) or hexamethyleneimine (DOXH). The tetrazolium dye colorimetric assay was used to determine the cytotoxic activity...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید